Isolated Respiratory Failure As the Presenting Symptom of Muscle-Specific Kinase Myasthenia Gravis: A Case Report and Literature Review

Overview

Journal Case Rep Neurol

Publisher Karger

Specialty Neurology

Date 2024 Oct 30

PMID 39474296

Authors

Hassan Doumiati

Ali Ezzeddine

Affiliations

Soon will be listed here.

Abstract

Introduction: Anti-MuSK antibodies obstruct MuSK binding sites, leading to acetylcholine receptor (AChR) displacement within the postsynaptic membrane. MuSK MG patients often exhibit bulbar involvement and respiratory crises, setting them apart from other MG subtypes.

Case Presentation: A case of a 51-year-old male with MuSK MG that presented as isolated respiratory failure was compared to similar cases in the literature. The objectives were to explore the varied clinical presentations, treatment approaches, and outcomes, and to better understand the management of this subgroup of MG. The patient responded well to treatment with pyridostigmine, steroids, and intravenous immunoglobulins and immunosuppressive therapy.

Conclusion: A review of the literature revealed varied clinical presentations and treatment approaches among reported cases. Long-term prognosis appears favorable, requiring ongoing immunosuppressive management. Although the reported outcomes of MuSK MG patients with respiratory insufficiency show substantial heterogeneity, long-term prognosis appears favorable.

References

Huijbers M, Zhang W, Klooster R, Niks E, Friese M, Straasheijm K . MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013; 110(51):20783-8. PMC: 3870730. DOI: 10.1073/pnas.1313944110. View

Lau A, Chan A, Mok V . Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment. Hong Kong Med J. 2011; 17(1):77-9. View

Witoonpanich R, Dejthevaporn C, Pulkes T, Tunlayadechanont S, Boonkongchuen P, Pongpakdee S . Prevalence, clinical features and treatment outcomes of patients with myasthenia gravis positive for antibodies to muscle-specific kinase in Thailand. J Clin Neurosci. 2013; 20(5):707-9. DOI: 10.1016/j.jocn.2012.03.047. View

Evoli A, Tonali P, Padua L, Lo Monaco M, Scuderi F, Batocchi A . Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126(Pt 10):2304-11. DOI: 10.1093/brain/awg223. View

Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y . Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005; 57(2):289-93. DOI: 10.1002/ana.20341. View

Evoli A, Bianchi M, Riso R, Minicuci G, Batocchi A, Servidei S . Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008; 1132:76-83. DOI: 10.1196/annals.1405.012. View

Koneczny I, Stevens J, De Rosa A, Huda S, Huijbers M, Saxena A . IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2016; 77:104-115. DOI: 10.1016/j.jaut.2016.11.005. View

Stickler D, Massey J, Sanders D . MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol. 2005; 116(9):2065-8. DOI: 10.1016/j.clinph.2005.06.003. View

Gilhus N, Verschuuren J . Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015; 14(10):1023-36. DOI: 10.1016/S1474-4422(15)00145-3. View

10.

McConville J, Farrugia M, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J . Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004; 55(4):580-4. DOI: 10.1002/ana.20061. View

11.

Evoli A, Alboini P, Damato V, Iorio R, Provenzano C, Bartoccioni E . Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2017; 1412(1):82-89. DOI: 10.1111/nyas.13518. View

12.

Pasnoor M, Wolfe G, Nations S, Trivedi J, Barohn R, Herbelin L . Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2009; 41(3):370-4. DOI: 10.1002/mus.21533. View

13.

Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic L, Stojanovic V . The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry. 2005; 76(8):1099-102. PMC: 1739764. DOI: 10.1136/jnnp.2004.052415. View

14.

Niks E, Kuks J, Verschuuren J . Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry. 2006; 78(4):417-8. PMC: 2077782. DOI: 10.1136/jnnp.2006.102517. View

15.

Benamer H, Bredan A . The epidemiology of myasthenia gravis in Arab countries: a systematic review. Muscle Nerve. 2014; 51(1):144-5. DOI: 10.1002/mus.24350. View

16.

Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C . Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007; 68(8):609-11. DOI: 10.1212/01.wnl.0000254620.45529.97. View

17.

Baalbaki J, Agha M, Jaafar N, Yamout B, Moussa S . Autoantibodies, clinical phenotypes and quality of life in Lebanese patients with myasthenia gravis. Intractable Rare Dis Res. 2023; 12(2):122-125. PMC: 10242391. DOI: 10.5582/irdr.2023.01009. View

18.

Tsai C, Howard Jr J, Mehrabyan A . A Case of MuSK Myasthenia Gravis Presenting With Persistent Respiratory Insufficiency. J Clin Neuromuscul Dis. 2021; 23(1):39-42. DOI: 10.1097/CND.0000000000000374. View

19.

Guptill J, Sanders D, Evoli A . Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011; 44(1):36-40. DOI: 10.1002/mus.22006. View

20.

Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos S . Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol. 2009; 16(8):925-30. DOI: 10.1111/j.1468-1331.2009.02624.x. View